To further support the efficacy of catheter ablation in T2DM individuals, the combined use of SGLT2 inhibitors and GLP-1 RAs may synergistically attenuate AF burden by inhibiting the progression of DM-related atrial cardiomyopathy through complementary pathways. The gene discussed is SLC5A2; the disease is diabetes mellitus.